Skip to Content

Korsuva FDA Approval Status

FDA Approved: No
Brand name: Korsuva
Generic name: difelikefalin
Company: Cara Therapeutics, Inc.
Treatment for: Chronic Kidney Disease-Associated Pruritus

Korsuva (difelikefalin) is a selective peripheral kappa opioid receptor agonist in development for the treatment of moderate-to-severe pruritus in hemodialysis patients.

Development Timeline for Korsuva

Dec 28, 2020Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Korsuva Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
Aug  7, 2018Cara Therapeutics Doses First Patient in Second Pivotal Phase 3 Efficacy Trial of Korsuva (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.